Correction Notice for Figure 1 in the Study on Antibiotic De-Escalation
Overview
This report addresses a correction made to Figure 1 in the study on antibiotic de-escalation in adults with community-onset sepsis. The value in the exclusion box for positive PSA test findings was updated to 1669.
Background
Antibiotic de-escalation is a critical component of antimicrobial stewardship, particularly in the management of sepsis. The timely adjustment of antibiotic therapy based on clinical and microbiological data can reduce unnecessary antibiotic exposure and associated adverse effects. Accurate reporting in clinical studies is essential to ensure the validity of findings and recommendations.
Data Highlights
No numerical data or trial results were presented in the correction notice.
Key Findings
- The exclusion value for positive PSA test findings in Figure 1 was corrected to 1669.
- Antibiotic de-escalation is recommended when microbiologic diagnoses are available.
- De-escalation practices are associated with reduced antibiotic days and shorter hospital stays.
- Guidelines emphasize the importance of timely and appropriate empiric therapy in sepsis management.
- Clinical improvement by days 3-4 is a predictor for successful de-escalation.
Clinical Implications
Healthcare professionals should ensure accurate data representation in clinical studies to maintain the integrity of research findings. Adhering to guidelines on antibiotic de-escalation can enhance patient outcomes and minimize the risks associated with prolonged antibiotic use.
Conclusion
The correction of Figure 1 is crucial for the accurate interpretation of the study's findings on antibiotic de-escalation. Ongoing adherence to updated clinical guidelines remains essential in the management of sepsis.
References
- JAMA Internal Medicine, 2025 -- Antibiotic De-Escalation in Adults Hospitalized for Community-Onset Sepsis
- Intensive Care Medicine — Correction Notice: Impact of Daily Antiseptic Bathing with Octenidine on Bacteremia and Multidrug-Resistant Organisms Acquired in the ICU: A Multicenter, Cluster-Randomized, Double-Blind, Placebo-Controlled, Crossover Trial
- Infection — Correction Notice: Assessment of Systemic Inflammatory Response After Transcatheter Aortic Valve Replacement: A Framework for Judicious Antibiotic Administration
- Infection — Amendment to: Clinical Insights on Dalbavancin Use for Gram-Positive Skin and Soft Tissue Infections, as well as Bone and Joint Infections
- Intensive Care Medicine — Revised Approach for Managing Hospitalized Pneumonia Patients Unresponsive to Treatment
- Surviving Sepsis Campaign Adult Guidelines | SCCM
- Antibiotic De-Escalation in Adults Hospitalized for Community-Onset Sepsis | JAMA Internal Medicine | DeepDyve
- Biomarker-Guided Antibiotic Duration for Hospitalized Patients With Suspected Sepsis: The ADAPT-Sepsis Randomized Clinical Trial | Trials | JAMA | JAMA Network
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
